Idorsia reports FY results
Source: SeekingAlpha
2026-02-26 11:54:02 ET
More on Idorsia
- Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Seeking Alpha’s Quant Rating on Idorsia
- Historical earnings data for Idorsia
- Financial information for Idorsia
Read the full article on Seeking Alpha
For further details see:
Idorsia reports FY results
Idorsia Ltd Registered Shares
NASDAQ: IDRSF
IDRSF Trading
0.0% G/L:
$4.32 Last:
200 Volume:
$4.32 Open:
IDRSF Latest News
January 05, 2026 11:45:00 am
Idorsia's daridorexant in women during menopausal transition age with insomniaDecember 10, 2025 01:00:00 am
New Hypertension publication underscores aprocitentan's potential in managing hypertension patients with CKDNovember 10, 2025 11:45:00 am
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertensionNovember 05, 2025 11:45:00 am
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
